Sat, Dec 20, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Private Equity Strategies

Dealmakers Q&A: Waud Capital Merges Portfolio Companies Early On

Monday, August 26, 2013

By: Bailey McCann, Private Equity Strategies

Waud Capital Partners focuses on middle-market growth equity investments, buyouts, industry consolidations and recapitalizations. Since its founding in 1993, the firm has completed more than 150 investments across industries, and has approximately $1bn of capital under management.

The firm recently announced the merger of two of its portfolio companies - Adreima and Optimum Outcomes, marking the first time Waud has merged two of its own portfolio companies. The merger is also notable as it took place early on in the investment lifecycle, which means that Waud will continue to be involved with the new entity well into the future.

“We always thought that there was a possibility both companies could be merged, but it was never a specific plan,” explains David Neighbours, Partner at Waud Capital Partners, in an interview with Private Equity Strategies. “We found there was a great opportunity to combine services, and share customers between the two businesses in a way that would be beneficial for both companies and their customers.”

Adreima, is a national provider of clinically integrated revenue cycle services. Optimum Outcomes, is a national provider of patient-focused account resolution services. Both companies have a roughly similar target audience of 5-6,000 hospitals in the US. The companies focus on the revenue cycle of hospitals, providing services around eligibility and registration staffing; clinical audit and denial prevention; and receivables management and self-pay/bad debt account resolution.

Both companies have been serving their respective clients for a number of years, Adreima was founded in 1990, and Optimum has been in business for 25 years.

Waud itself is a generalist firm in terms of the portfolio companies it looks at, however, Neighbors notes that they have a significant health care group and will continue to pursue this industry. The firm typically invests $20-100m, as a controlling interest. From there, Waud looks at how it can best grow portfolio companies, in this case that growth came from being acutely aware of how two separate portfolio companies work together in the same industry.

“Over time, merging the two companies really started to become a natural thing to do as they both evolved and started working together,” Neighbours says. “This will allow us to expand services to customers, and entrench those services, making it harder for hospitals to switch vendors.”

“We are acutely aware that each touch point of a patient’s healthcare experience has the ability to influence that patient’s perception of the provider. With the full spectrum of services now offered by the combined company, we are even better positioned to ensure and facilitate a positive patient experience, from initial registration all the way through final account resolution,” says Robb Cass, President of Optimum Outcomes.

The combined company will maintain the Adreima name and will be headquartered in suburban Chicago. The new business will have 1,100 dedicated employees, including 200 specialized physicians, nurses and coders, serving 600 hospitals and providers across 36 states. Robert Willhelm, the current CEO of Adreima will be CEO of this iteration, and Robb Cass, current President of Optimum Outcomes, will lead the patient-focused account resolution division.

The new organization will continue to operate from seven regional locations (Phoenix, Raleigh, Jacksonville, Fort Lauderdale, Los Angeles, Birmingham and Bloomfield, New Jersey). The company’s bad debt division will continue to operate as Optimum Outcomes.

“This is the first time we’ve ever merged two companies we have invested in so we plan to spend the balance of 2013 focusing on integration. In 2014 we will look at ways to continue growth, potentially through new acquisition opportunities, this is still a long term investment for us,” Neighbours says.

Waud had a controlling interest in both companies before the merger, and will maintain a controlling interest in the merged entity. Debt financing for the merger was provided by BMO, Regions Bank, Capital One Bank and Bregal Sagemount.

 
This article was published in Opalesque's Private Equity Strategies our monthly research update on the global private equity landscape including all sectors and market caps.
Private Equity Strategies
Private Equity Strategies
Private Equity Strategies
Private Equity Strategies


Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. Opalesque Exclusive: U.S. legal receivables fund launched in August[more]

    Benedicte Gravrand, Opalesque Geneva for New Managers: Investing in asset-backed receivables is a strategy that has been an integral part of the alternative investment space within the overall fixed income asset c

  5. Comment - High fees and low performance hit hedge funds[more]

    From FT.com: Disenchantment over high fees and lackluster performance may finally be turning the tide against hedge funds, fresh data suggest. Despite generally weak returns since the global financial crisis, hedge funds have enjoyed positive net inflows every year since 2010. This helped assets und